15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      NIA Interventions Testing Program: Investigating Putative Aging Intervention Agents in a Genetically Heterogeneous Mouse Model

      discussion
      a , * , b , c , d
      EBioMedicine
      Elsevier

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The Interventions Testing Program (ITP) was established by the National Institute on Aging (NIA) to investigate the potential of dietary interventions to promote healthy aging (https://www.nia.nih.gov/research/dab/interventions-testing-program-itp). The ITP uses a four-way cross genetically heterogeneous mouse model (UM-HET3) to reduce the impact of strain-specific characteristics on outcomes (Nadon et al., 2008). Lifespan tests are done in parallel, using the same protocol, at three independent sites to increase robustness of the findings. Population sizes are large enough that the protocol will detect a 10% change in mean lifespan, in either sex, with 80% power, pooling data from as few as two sites. Standard operating procedures were designed to maintain as much consistency as possible among the three sites, including caging, bedding, food, and light/dark cycles; a more in-depth discussion of the SOP has been published (Nadon et al., 2015). Interventions for testing are proposed by the research community through an annual call-for-proposals, and proposed compounds have ranged from drugs and dietary supplements to micronutrients and metabolic intermediates. Before the ITP embarks on testing a compound, pilot studies are done to maximize the chances of a successful test. Goals of the pilot studies include demonstrating that the compound is stable in food and that it is uniformly mixed in the food, determining blood levels after short-term treatment (bioavailability), showing evidence of an effect from the short-term treatment (bioactivity), and in some cases, testing for toxicity. The testing of rapamycin is a good case-in-point for analyzing stability of the compound in the food. Pilot analysis showed that about 85% of the rapamycin was degraded by the food preparation process, leading to the use of microencapsulation to deliver stable doses of the compound in food (Harrison et al., 2009). The list of all compounds tested by the ITP and in progress is on the ITP website at https://www.nia.nih.gov/research/dab/interventions-testing-program-itp/compounds-testing. To date, six compounds have shown significant extension of lifespan: • Aspirin – males only (Strong et al., 2008); • Rapamycin – males and females (females > males) (Harrison et al., 2009, Miller et al., 2011, Miller et al., 2014); • 17αEstradiol – males only (Harrison et al., 2014); • Acarbose – males and females (males > > females) (Harrison et al., 2014); • Nordihydroguaiaretic acid (NDGA) – males only (Strong et al., 2008, Harrison et al., 2014); • Protandim® - males only (Strong et al., 2016). The positive findings illustrate some important aspects for aging interventions research. The effective interventions appear to include several disparate mechanisms, demonstrating that many cellular pathways might be exploited to influence lifespan and aging. Rapamycin modulates the nutrient-sensing pathways via its interaction with mTOR (Harrison et al., 2009). Acarbose was anticipated to work as a caloric restriction mimetic due to its ability to reduce the rate of absorption of carbohydrates, but its mechanism of action appears more complex, since caloric restriction results in significant lifespan extension in both male and female UM-HET3 mice (Flurkey et al., 2010), while the effects of acarbose were much larger in males (Harrison et al., 2014). Aspirin is known for its anti-inflammatory and antioxidant activities, NDGA also has anti-inflammatory and antioxidant activities, 17αEstradiol has neuro-protective properties independent of binding to the estrogen receptor, and Protandim® activates Nrf2 transcriptional regulator (Strong et al., 2008, Strong et al., 2016). This diverse group of interventions demonstrates the complex nature of the biology of aging. Another major surprise is the extent of sex differences in response to the interventions. Four of the six positive interventions only worked in one sex, and the two that had an effect in both sexes showed sex-specific differences in the extent of the effect. Blood levels of a compound sometimes differed between males and females, but that did not always explain the sex difference in lifespan extension. For rapamycin, achieving approximately equivalent blood levels in males and females by treating with different doses did result in similar increases in lifespan (Miller et al., 2014). But for NDGA, even at doses giving similar blood levels in males and females, females still did not respond (Harrison et al., 2014). The ITP's findings illustrate how important it is to examine the effects of interventions in both sexes and suggest that further studies on the mechanism of these sex effects may yield important insights into the underlying biology, and guidance for eventually clinical studies. Lifespan, while a valuable measurement in rodent model studies, does not entirely capture the impact of aging interventions. Aging is a complex process, with many physiological systems affected, and not all at the same time or rate. Measurements of a wide range of endpoints relevant to health and maintenance of function will help to clarify the relationship of aging to function and disease, and may also document drug effects pertinent to human health maintenance. The ITP is developing a panel of measurements to assess health and function that will be used across cohorts to add to the information the lifespan studies provide. Studies in the mouse have contributed significantly to our understanding of aging and interventions to promote healthy aging. Testing both sexes and avoiding the use of a single inbred strain are key features that will enhance translation of the findings. A power analysis is essential to get the most value from experiments, and standardized protocols allow for cross-experimental comparisons. Multi-site testing protocols also add value to the design because some site-to-site variation is unavoidable even with every effort made to minimize differences between sites. For example, the ITP has consistently found that control male mice at one site weigh less and live longer than the control males at the other two sites, even though each site uses the same food preparations and standardized husbandry (Strong et al., 2012). Positive findings replicated in different labs are inherently stronger than a finding from one lab, while disparate findings convey a valuable caution and emphasize the need for replications in other laboratories, other mouse stocks, and other drug doses. In summary, the ITP program, now in its 13th year, has become a major contributor to the biogerontology research community, providing new insights into the biology of aging, new tools for probing the relationships among cells, aging, and disease, and new ideas about how best to translate studies in basic biogerontology into human investigation, and, eventually, into the clinic. The ITP is funded by the National Institutes of Health grants U01-AG022303 to RAM, U01-AG022308 to DEH, and U01-AG022307 to RS.

          Related collections

          Most cited references5

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer

          Summary The National Institute on Aging Interventions Testing Program (ITP) evaluates agents hypothesized to increase healthy lifespan in genetically heterogeneous mice. Each compound is tested in parallel at three sites, and all results are published. We report the effects of lifelong treatment of mice with four agents not previously tested: Protandim, fish oil, ursodeoxycholic acid (UDCA) and metformin – the latter with and without rapamycin, and two drugs previously examined: 17‐α‐estradiol and nordihydroguaiaretic acid (NDGA), at doses greater and less than used previously. 17‐α‐estradiol at a threefold higher dose robustly extended both median and maximal lifespan, but still only in males. The male‐specific extension of median lifespan by NDGA was replicated at the original dose, and using doses threefold lower and higher. The effects of NDGA were dose dependent and male specific but without an effect on maximal lifespan. Protandim, a mixture of botanical extracts that activate Nrf2, extended median lifespan in males only. Metformin alone, at a dose of 0.1% in the diet, did not significantly extend lifespan. Metformin (0.1%) combined with rapamycin (14 ppm) robustly extended lifespan, suggestive of an added benefit, based on historical comparison with earlier studies of rapamycin given alone. The α‐glucosidase inhibitor, acarbose, at a concentration previously tested (1000 ppm), significantly increased median longevity in males and 90th percentile lifespan in both sexes, even when treatment was started at 16 months. Neither fish oil nor UDCA extended lifespan. These results underscore the reproducibility of ITP longevity studies and illustrate the importance of identifying optimal doses in lifespan studies.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Evaluation of resveratrol, green tea extract, curcumin, oxaloacetic acid, and medium-chain triglyceride oil on life span of genetically heterogeneous mice.

            The National Institute on Aging Interventions Testing Program (ITP) was established to evaluate agents that are hypothesized to increase life span and/or health span in genetically heterogeneous mice. Each compound is tested in parallel at three test sites. It is the goal of the ITP to publish all results, negative or positive. We report here on the results of lifelong treatment of mice, beginning at 4 months of age, with each of five agents, that is, green tea extract (GTE), curcumin, oxaloacetic acid, medium-chain triglyceride oil, and resveratrol, on the life span of genetically heterogeneous mice. Each agent was administered beginning at 4 months of age. None of these five agents had a statistically significant effect on life span of male or female mice, by log-rank test, at the concentrations tested, although a secondary analysis suggested that GTE might diminish the risk of midlife deaths in females only.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Design of aging intervention studies: the NIA interventions testing program.

              The field of biogerontology has made great strides towards understanding the biological processes underlying aging, and the time is ripe to look towards applying this knowledge to the pursuit of aging interventions. Identification of safe, inexpensive, and non-invasive interventions that slow the aging process and promote healthy aging could have a significant impact on quality of life and health care expenditures for the aged. While there is a plethora of supplements and interventions on the market that purport to slow aging, the evidence to validate such claims is generally lacking. Here we describe the development of an aging interventions testing program funded by the National Institute on Aging (NIA) to test candidate interventions in a model system. The development of this program highlights the challenges of long-term intervention studies and provides approaches to cope with the stringent requirements of a multi-site testing program.
                Bookmark

                Author and article information

                Contributors
                Journal
                EBioMedicine
                EBioMedicine
                EBioMedicine
                Elsevier
                2352-3964
                02 December 2016
                July 2017
                02 December 2016
                : 21
                : 3-4
                Affiliations
                [a ]Division of Aging Biology, National Institute on Aging, Bethesda, MD 20892, USA
                [b ]Geriatric Research, Education and Clinical Center and Research Service, South Texas Veterans Health Care System, Department of Pharmacology, Barshop Institute for Longevity and Aging Studies, The University of Texas Health Science Center at San Antonio, TX 78229, USA
                [c ]Department of Pathology and Geriatrics Center, University of Michigan, Ann Arbor, MI 48109, USA
                [d ]The Jackson Laboratory, Bar Harbor, ME 04609, USA
                Author notes
                [* ]Corresponding author at: Division of Aging Biology, National Institute on Aging, 7201 Wisconsin Ave., GW3N300, Bethesda, MD 20892, USA.Division of Aging BiologyNational Institute on Aging7201 Wisconsin Ave., GW3N300BethesdaMD20892USA nadonn@ 123456nia.nih.gov
                Article
                S2352-3964(16)30554-0
                10.1016/j.ebiom.2016.11.038
                5514387
                27923560
                808e027c-1e43-4e64-9176-72471782b136

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 14 October 2016
                : 28 November 2016
                : 30 November 2016
                Categories
                In Focus

                Comments

                Comment on this article